Intellia Therapeutics (NASDAQ:NTLA) Shares Up 10.7% After Analyst Upgrade

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) were up 10.7% during trading on Monday after Leerink Partners raised their price target on the stock from $27.00 to $29.00. Leerink Partners currently has an outperform rating on the stock. Intellia Therapeutics traded as high as $15.35 and last traded at $15.2540. Approximately 9,385,176 shares changed hands during mid-day trading, an increase of 78% from the average daily volume of 5,264,466 shares. The stock had previously closed at $13.78.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright lifted their price target on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Royal Bank Of Canada raised their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday. Citizens Jmp increased their price target on Intellia Therapeutics from $21.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Finally, Wells Fargo & Company lifted their price objective on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday. Ten analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and an average price target of $19.14.

Insider Buying and Selling

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Schroder Investment Management Group boosted its position in shares of Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after purchasing an additional 382,425 shares in the last quarter. Marex Group plc purchased a new position in Intellia Therapeutics during the second quarter valued at $5,849,000. JPMorgan Chase & Co. boosted its holdings in Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after acquiring an additional 396,858 shares in the last quarter. AXQ Capital LP purchased a new stake in shares of Intellia Therapeutics in the second quarter worth $285,000. Finally, SG Americas Securities LLC grew its stake in shares of Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock worth $2,264,000 after acquiring an additional 92,485 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 11.9%

The firm has a fifty day moving average price of $12.09 and a two-hundred day moving average price of $13.10. The stock has a market capitalization of $1.61 billion, a P/E ratio of -3.55 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.27) earnings per share. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.